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ABSTRACT Osteoarthritis (OA) is a chronic condition that impacts quality of life and functionality for which consumers
often seek dietary supplements to provide some relief. The purpose of this double-blind, placebo-controlled clinical trial was
to assess the safety and efficacy of a water-soluble chicken eggshell membrane hydrosylate (WSEM) dietary supplement
(BiovaFlex) 450 mg daily on knee function, mobility, and general health and well-being in 88 adults with OA randomized
into intervention (n = 44) or placebo (n = 44) groups. Outcomes were assessed periodically over 12 weeks, including the
Western Ontario McMaster Osteoarthritis Index (WOMAC), the six-minute walk test (6MWT), knee range of motion (ROM)
testing, and safety. Normalized analysis (improvement over baseline) showed that the poorest initial performers benefited the
greatest from the WSEM by day 5 in the 6MWT, with the rest of the population showing significant improvement over
placebo by week 12. The normalized WOMAC Stiffness score was also significantly improved over placebo by day 5
(P < .05). Without normalization, no statistically significant improvements were seen in WOMAC, 6MWT, and ROM testing.
The Product was also found to be safe in this study. In conclusion, daily consumption of WSEM significantly enhanced
average individual physical capacity (walking distance and ability), reduced stiffness by the fifth day of supplementation with
the greatest benefit seen by the most compromised individuals, and was maintained over 12 weeks. A WSEM dietary
supplement may offer a safe option for relief from symptoms and increased mobility for those with OA.
KEYWORDS:  cartilage  chondroitin  hyaluronic acid  collagen  glucosamine  dietary supplement  osteoarthritis
 water soluble egg shell membrane
INTRODUCTION
O steoarthritis (OA) is a chronic joint condition thataffects millions of people worldwide, with significant
impact on quality of life, activities of daily living, and health
care costs.1–3 According to The World Health Organization
(WHO) Global Burden of Disease Study 2010, hip and knee
OA is the 11th leading cause of disability and is predicted to
increase.4 There is no standard for treatment and what is
available is typically focused more on pain alleviation by a
combination of pharmacological and nonpharmacological
approaches rather than curative treatment. Even when pain
alleviation protocols are prescribed, only half of the patients
experience pain reduction.5 Some improvements may be
achieved by weight-loss and physical activities, including
physical therapy; however, this often does not lead to a full
alleviation of symptoms.6 Although surgery is often the only
option for more severe cases it is not always an option due to
cost or co morbidities.7,8 Therefore, there is a need to in-
vestigate alternative therapeutics and nutritional supple-
ments as an option for symptom management. Perhaps one
of the most known nutritional supplement combinations to
be investigated is chondroitin-sulfate, glucosamine, and
hyaluronic acid.4–6 In a double-blind, placebo-controlled
study, subjects taking a herbal extract in combination with
hyaluronate and glucosamine for 8 weeks demonstrated a
faster return to joint health and greater quality of life.9 In
another study, the effect of UP1306, a standardized, pro-
prietary extract of Morus alba and Acacia catechu, com-
pared with glucosamine chondroitin was evaluated in 135
adults with OA of the knee in a randomized, placebo-
controlled, 12-week study. Similar improvements were
found for the UP1306 group and the placebo group based on
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the Western Ontario McMaster Osteoarthritis Index (WO-
MAC) scales (discomfort, stiffness, and activities of daily
living) as well as range of motion (ROM) and distance
walked measures. Degradation of cartilage as measured by
urinary C-telopeptides of type II collagen was significantly
less at 12 weeks in subjects given UP1306. The authors
suggested that early treatment with UP1306 might act to
prevent joint cartilage damage.10 A pilot clinical trial in-
vestigated the effect of daily supplementation with oral
hyaluronic acid extracted from chicken combs (Hyal-Joint,
Bioberica, Spain). Twenty subjects aged ‡40 years with knee
OA (pain for at least 15 days in the previous month, symp-
toms present for ‡6 months, Kellgren/Lawrence score ‡2)
participated in a randomized, double-blind, placebo-controlled
trial. Ten subjects received the study product (80 mg/day)
and 10 received placebo for 8 weeks. The WOMAC scale
and a quality-of-life questionnaire (the Short Form-36 [SF-
36v2]) were administered at baseline and after 4 and 8
weeks of treatment. The results for subjects in both groups
showed statistically significant improvements in WOMAC
Pain, Stiffness, and Physical Function subscales, and in the
aggregate WOMAC score, with higher magnitudes of change
in the treatment group for WOMAC Physical Function and
Total symptoms. Within-group changes indicated signifi-
cant improvement for both groups on the SF-36v2 at 4 and 8
weeks; greater change occurred in the treatment group for
bodily pain and social functioning. The results indicated
that daily supplementation with oral hyaluronic acid from
a natural extract of chicken combs was useful in enhanc-
ing several markers of quality of life in adults with OA of
the knee.11
Eggshell membrane (EM) is a naturally rich source of
combined protein, elastin, collagen, glucosamine, chondroi-
tin, and hyaluronic acid and has been studied as a treatment
for management of symptoms related to OA. EM’s high
content of bioactive components, as well as properties of
moisture retention and biodegradability, suggests that it
has potential use for clinical,12 cosmetic, nutraceutical, and
nanotechnology applications.13 Studies have demonstrated
that EM leads to a reduction in the production of pro-
inflammatory cytokines, such as interleukin-1 beta and tu-
mor necrosis factor-alpha both in vitro14 and in vivo.15 EM
has been shown to improve recovery from exercise-induced
joint pain (day 8), decrease stiffness (day 4), and reduce
discomfort immediately after exercise (stiffness, day 7) in
postmenopausal women taking 500 mg once daily for 2
weeks. In the same study, a decrease in the cartilage degra-
dation biomarker CTX-II occurred.16 Two 1-month, open-label,
pilot clinical studies with 11 and 28 subjects, respectively,
were conducted to evaluate the efficacy and safety of EM
for the relief of pain and discomfort associated with joint
and connective tissue disorders. The results indicated that
500 mg of EM taken once daily significantly reduced pain,
both within 7 days and over 30 days.17 A follow-up, ran-
domized, double-blind study of 67 subjects revealed that
500 mg of EM taken once per day significantly reduced joint
pain and stiffness compared with placebo within 10 days and
maintained over 60 days.18
Water-Soluble Eggshell Membrane (WSEM) is a novel,
patented, water-soluble version of EM (United States Patent
Numbers: 7,584,909, 8,056,844, 8,197,852, 8,211,477, and
8,425,943) containing naturally occurring collagen, elastin,
glycosaminoglycans (GAGs), and proteins, which typically
are essential for maintaining healthy articular cartilage and
the surrounding synovium. GAGs, one of the components of
WSEM, are large, linear polysaccharides constructed of
repeating disaccharide units with the primary configurations
containing an amino sugar (either GlcNAc or GalNAc) and a
uronic acid (either glucuronic acid and/or iduronic acid).
Examples include hyaluronan, chondroitin, dermatan, hep-
arin/heparan, and keratan, some of which have been shown
to benefit joint health in multiple studies.9–11,13,15–18
In a randomized, double-blind, placebo-controlled cross-
over study of 22 adults with joint pain/stiffness, Jensen et al.
reported that supplementation of 450 mg WSEM (Biova-
Flex) for 4 weeks led to a significant improvement in
quality of life, physical function,18 ROM of the shoulder
(P < .01), neck, spine, hips, and knees compared with placebo
(P < .05). Physical activity levels were significantly higher
after WSEM than after placebo consumption (P < .05). Sub-
group analysis of those who participated in the study in the
winter season showed improvement of lower back pain af-
ter 5 days of WSEM consumption compared with placebo
consumption (P < .05).17 These findings demonstrated ef-
ficacy of the intervention, deserving continued exploration
and follow-up.
Therefore, to further evaluate the WSEM product, this
randomized, double-blind, placebo-controlled trial was un-
dertaken, specifically in adults who were experiencing symp-
toms associated with OA of the knee to the extent that it was




This was a randomized, double-blind, placebo-controlled,
parallel-design, prospective study conducted at a single re-
search site located in Springfield, Missouri, USA (QPS-
BioKinetics). The purpose of the study was to assess the
safety and efficacy of the study product [BiovaFlex—Study
Product, 450mg daily] on knee function, mobility, and
general health and well-being as measured by changes in
vitals and by changes in general blood work in subjects with
OA at specific time points over an 85-day (12-week) pe-
riod. The dose was selected based on previously established
studies. In general, after undergoing phone- and in-person
screening, and after signing an informed consent, subjects
were randomized in a 1:1 manner to either study product or
placebo group. The study (CSP#87117) was approved by
the Bio-Kinetic Clinical Applications Institutional Review
Board on November 17, 2018 and executed by QPS Mis-
souri (Springfield, MO).
The study consisted of adult subjects recruited by local
advertisements in the community aged 35–65 years (inclusive)
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with a body mass index (BMI) <35 kg/m2 (normal weight
through Class I obesity). To confirm the presence of OA, the
subjects, by self-report, had to have experienced knee pain
for at least 15 of the prior 30-day before screening as well as
other symptoms of knee pain for at least 6 months, with at
least 3 of the following indicators as taken from the Amer-
ican College of Rheumatology Clinical Classification Cri-
teria for OA diagnosis of the knee: be older than 50 years of
age; report less than 30 min of morning stiffness; crepitus on
active motion; bony tenderness; bony enlargement; and/or
no palpable warmth of synovium. Other than the indication
of OA, subjects had no known egg allergy, and no clinically
significant medical conditions based on physical exami-
nation, medical history, and screening laboratory results.
Further, subjects could not have undergone intra-articular
treatment in either knee (e.g., visco-supplementation with
hyaluronic acid products or corticosteroid injections) within
12 weeks of randomization.19
The subjects were advised to stop any use of over-the-
counter nonsteroidal anti-inflammatory drugs or pain relief
products for at least 14 days before the randomization visit.
In addition, the subjects were advised to stop the use of
acetaminophen for 24 h before the randomization visit to
permit an accurate baseline assessment of the WOMAC
scale and its subscales.
All subjects were assessed at the baseline visit by the
Western Ontario McMaster University Osteoarthritis Index
(WOMAC), physical performance—by the six-minute walk
test (6MWT) (weight-bearing exercise), and joint ROM for
the knee by using a standard goniometer. In addition, all
subjects utilized a daily diary to record any use of rescue
medication between study visits (rescue medicine, 500 mg
acetaminophen to no greater than 2000 mg allowed). Sub-
jects underwent repeat clinic visit testing on days 5, 28, 56,
and 84 after the randomization visit.
Study assessments
WOMAC is widely used in the evaluation of overall well-
being and hip and knee OA.20 This study concentrated
on knee OA. The WOMAC consists of a self-administered
questionnaire of 24 items divided into 3 subscales—Pain
(5 items): during walking, using stairs, in bed, sitting or
lying, and standing upright; Stiffness (2 items): after first
waking and later in the day; and Physical function (17 items):
using stairs, rising from sitting, standing, bending, walking,
getting in/out of a car, shopping, putting on/taking off socks,
rising from bed, lying in bed, getting in/out of bath, sitting,
getting on/off toilet, heavy domestic duties, and light do-
mestic duties. The study subjects described their current
experience by checking one of the five numbered boxes that
formed a rating scale, which varied from 0 = none, 1 = slight,
2 = moderate, 3 = very, and 4 = extremely. In the begin-
ning of the study, subjects answered the WOMAC and this
was considered the baseline. For all study visits after base-
line, subjects were asked to reflect back to baseline that
is now termed ‘‘since starting this study’’ for scoring the
WOMAC.20,21
The 6MWT is a submaximal exercise test that entails
measurement of distance walked over a span of 6 min.22,23
This test measures functional ability to ambulate in a
weight-bearing situation. The total distance covered over the
6 min is documented, allowing for comparisons over time
and between individuals in a cohort, to determine any pos-
itive, neutral, or negative impacts of an intervention. In-
cremental distances over baseline for individuals were also
calculated at each time point and were correlated to the
individual’s baseline performance.
The ROM testing included a standardized goniometer
( Jamar Goniometer 12 1/200—Model 7541; Patterson Med-
ical, Warrenville, IL) that was also employed for objective
evaluation of the ROM of the OA knee under zero stress
conditions.24 Subjects were measured for both flexion and
extension. While the subject is supine on the examining
table with the head of the table elevated to about 25–30, the
leg with the affected knee is extended by support under
the ankle so that the subject’s knee is raised slightly from the
table. Space is provided for the subject to fully extend their
knee actively with the angle of maximum extension mea-
sured on the third and final attempt. After the knee extension
measurement is taken (on the third trial), the bolster is re-
moved, and the subject is asked to place their foot as close as
possible to their buttocks (foot on the table). The subject is
given three trials to flex their knee as far as possible without
using their hands to assist them; the knee flexion measure-
ment is taken on the third trial.
Intervention products
This study evaluated Study Product Water-Soluble Egg-
shell Membrane Capsules (450 mg/day, CAS# 227025-36-6;
Biova, LLC, Johnson, IA) and matching placebo containing
the same excipients but without the active study product.
Both study product and placebo were manufactured by
Uckele Health & Nutrition (Contract Manufacturer, Bliss-
field, MI) for the study Sponsor, Biova, LLC. Subjects were
dosed once daily for the study duration. Compliance was
measured by dichotomous questionnaire and the standard
return pill-count method.
Safety assessment
Safety was monitored throughout the course of the study
by monitoring of blood pressure, liver function, kidney
function, blood sugar, general immunity, and red blood cell
activity (comprehensive metabolic panel, complete count
with differential urinalysis); physical exam, subjective
complaints, observed events, and adverse events (AEs) were
coded by MedDRA. All these were analyzed by appropriate
statistical techniques.
Statistical analysis
All analyses were conducted and presented with de-
scriptive statistics. For population statistics, the paired-t test
or Wilcoxon sign-rank test was used, as appropriate to the
data type, to compare the population measurements of both
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groups at each time point. The distributions of the individual
changes from baseline within each group were also com-
pared at all time points except the baseline. Fisher’s exact
test was utilized to compare the difference in proportions
between groups when the sample size was small; otherwise,
a chi-square test was employed. Significance was set at the
0.05 level (P < .05), with noted confidence intervals findings
noted. A nonhierarchal statistical approach was utilized to
treat each endpoint of interest separately as an independent
endpoint of interest.
In addition to the population statistics described earlier,
we tested the hypothesis that the performance of the worst
initial performers within each group would improve more
than those with the highest initial performance. This is a
correlative test that may only be performed on contin-
uum objective data (e.g., 6MWT or goniometer). Where
the range of a normally distributed population narrows,
the standard deviation (SD) (slope of the distribution on a
probability plot) gets smaller and can be compared by t-test
with that of another population.25,26 Further, the incremental
change in performance of each individual within a treatment
cohort can be correlated to their initial objective measured
performance.27,28 If the corresponding slope of that corre-
lation is statistically different from zero, then the hypothesis
that the worst performing individuals within the group see
the most benefit is verified.28,29 Similarly, the relative im-
provement seen in the worst performers can be compared
between the two treatment cohorts by the t-test of the two
performance improvement correlations. This comparative
statistical technique, defined herein as the Correlative Im-
provement Over Baseline Performance (CIOBP) test, was
applied to both the 6MWT and goniometer data sets.25–29
RESULTS
Study recruitment
This study recruited from local advertisements in the
community and screened 125 subjects to qualify and ran-
domize 88 (2 cohorts of 44 subjects per group). With a total
of 80 completing patients entering this two-treatment study,
the probability was calculated to be 90% that the study
would detect a treatment difference at a two-sided 0.05
significance level if the true difference between treatments
is 0.735 times the SD. With the same sample size, the
probability is 80% that the study will detect a treatment
difference at a two-sided 0.05 significance level if the
true difference between treatments is 0.635 times the SD.
The mean age of study participants was 53.3 – 7.61 years. The
study population was 72% female and 28% male. The mean
BMI was 28.20 – 2.73 kg/m2.
Efficacy results
The WOMAC self-assessment test was used to measure
the quality of life with pain/soreness, stiffness, physical
function, and a composite score of these three subscales.
Similar improvements in the composite WOMAC score and
each of the subscale scores are seen in both the Study Pro-
duct and Placebo groups for all quality-of-life measures
(Fig. 1). However, these improvements were not statistically
different between the two cohorts at any time point.
Because WOMAC is a self-assessment lacking a common
objective scale, an attempt was made to normalize these
data by looking at the individual changes from baseline at
each time point (Fig. 2). The baseline composite WOMAC
scores (SD) were 35.4 (19.69) and 31.6 (16.35) for the
Study Product and Placebo cohorts, respectively. The mean
changes from baseline for the composite WOMAC scores
were -3.6 (12.87), -6.0 (13.08), -8.7 (15.96), and -9.9
(16.77) for days 5, 28, 57, and 86, respectively, of the Study
Product cohort. The comparable composite mean change
from baseline scores were -1.9 (9.38), -6.8 (12.33), -8.4
(13.75), and -9.9 (12.89) for the Placebo cohort. The mean
change in the composite WOMAC score was statistically
different from baseline in the Study Product cohort at all
subsequent visits, 3 (day 5), 4 (day 28), 5 (day 57), and 6
(day 86) by t-test. The mean change from baseline in the
Placebo cohort was not statistically different from baseline
in visit 3 (day 5). It was statistically different from baseline
in visits 4 (day 28), 5 (day 57), and 6 (day 86) by t-test.
These data, however, showed no statistically significant dif-
ferences between the two cohorts by the Wilcoxon Rank-
Sum test.
WOMAC Pain Subscale. In the Study Product popula-
tion, the mean score (SD) of pain at baseline (Visit 2) was
7.0 (3.44) in the Study Product group and 6.6 (3.73) in the
Placebo group. The Pain subscale score distributions are
shown in Fig. 3). The mean change from baseline (SD) in the
Study Product group was -0.5 (2.39) at Visit 3 (day 5), -0.8
FIG. 1. Box plots of the total WOMAC score for both the Study
Product and Placebo cohorts. Both cohorts showed moderate im-
provement in scores over the course of the study, but pairwise
comparisons showed no significant differences between the two co-
horts at any time point (P > .05). WOMAC, Western Ontario
McMaster Osteoarthritis Index.
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(3.38) at Visit 4, -1.5 (3.48) at Visit 5, and -1.9 (3.35) at
Visit 6 (Fig. 4). The mean change from baseline (SD) in the
Placebo group was -0.6 (2.73) at Visit 3, -1.4 (3.11) at Visit
4, -1.8 (3.42) at Visit 5, and -2.0 (3.14) at Visit 6. When
compared with baseline, statistically significant decreases
were observed at Visits 5 and 6 in the Study Product group
and at Visits 4, 5, and 6 in the Placebo group. When com-
pared between groups, no statistically significant difference
was reported during the study period (P > .05).
WOMAC Stiffness Subscale. In the ITT population, the
mean score (SD) of stiffness at baseline (Visit 2) was 3.9
(1.66) in the Study Product group and 3.6 (1.56) in the
Placebo group, with the population distributions shown in
Table 1 for each time point. Chi-squared analysis of the
Study Product cohort suggests that a significant stiffness
improvement was observed by day 5 (P = .0181), but not at
later time points. The mean change from baseline (SD) in
the Study Product group was -0.6 (0.97) at Visit 3, -0.7
(1.70) at Visit 4, -1.2 (1.83) at Visit 5, and -1.3 (1.86) at
Visit 6, with the change-over-baseline score distributions for
each cohort shown in Table 2. The mean change from
baseline (SD) in the Placebo group was -0.1 (1.17) at Visit
3, -0.8 (1.59) at Visit 4, -1.0 (1.73) at Visit 5, and -1.3
(1.76) at Visit 6. Change from baseline was significantly
enhanced (five times better) in the Study Product group by
day 5 (significantly less stiffness) as compared with the
Placebo group [(0.6) - (0.1)/(0.1) · 100 = 500%; P < .05]. In
addition, when compared with baseline, statistically signif-
icant decreases were observed from Visit 3 to Visit 6 in the
Study Product group and from Visit 4 to Visit 6 in the
Placebo group. When compared between groups, no other
statistically significant difference was reported during the
study period.
WOMAC Physical function Subscale. In the Study
Product population, the mean score (SD) of physical func-
tion at baseline (Visit 2) was 24.4 (15.60) in the Study
Product group and 21.4 (12.39) in the Placebo group. The
mean change from baseline (SD) in the Study Product group
was -2.6 (11.10) at Visit 3, -4.5 (9.80) at Visit 4, -6.0
(12.24) at Visit 5, and -6.6 (12.93) at Visit 6. The mean
change from baseline (SD) in the Study Product Placebo
FIG. 2. Box plots of the individual improvements over baseline at
each time point for the total WOMAC self-assessment. The means of
the individual changes over baseline for the Study Product cohort
were statistically different from baseline at all time points (P < .05).
The Placebo cohort showed no statistically significant differences
over baseline at any time point by either statistical test (P > .05).
FIG. 3. Box plots of the individual WOMAC pain subscale scores.
No statistically significant changes were observed in the data either
between the Study Product and Placebo cohorts or over baseline
within each study cohort (P > .05).
FIG. 4. Box plots of the WOMAC change over baseline pain
subscale scores. The changes in the individual scores over baseline
were statistically significant for both the Study Product and Placebo
cohorts at days 56 and 84 (P < .05), and for the Placebo cohort at day
28, but not statistically different from each other at any time point
(P > .05).
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group was -1.2 (7.20) at Visit 3, -4.6 (9.73) at Visit 4, -5.6
(10.29) at Visit 5, and -6.7(9.53) at Visit 6. When compared
with baseline, statistically significant decreases were ob-
served from Visit 4 to Visit 6 in both Study Product and
Placebo groups. When compared between groups, no sta-
tistically significant difference was reported during the
study period.
Six-minute walk test. The aim of the test was to have the
subject walk as fast as comfortably possible for 6 min. The
distance covered over the full 6 min was recorded and
documented. The test conducted on day 0 was before the
first dose and provides a baseline for comparisons for
change from baseline. The probability plots (Fig. 5) show
the cumulative population distribution at each time point for
each cohort. The linearity of the probability plots shows that
the distances walked by the populations were normally
distributed at each time point. The average distance walked
at each time point was the same between the Study Product
and Placebo cohorts within 95% confidence at all time
points (Table 3). The average of the individual improve-
ments over baseline, however, shows that the entire study
population improves significantly (P = .0273) over that of
the Placebo control by day 84 (Table 3).
Although the mean group performance did not appear to
change, the variance in miles walked (as measured by the
slope of the probability curves in Fig. 5) changed consid-
erably from the baseline (day 0) to that observed at day 5 for
the Study Product group. The baseline SD for the Study
Product group was 0.0744 – 0.0018 mi and was 0.0512 –
0.0008 mi at day 5, which is different from the baseline at
P < .00001. This variance difference over baseline persists
throughout all the other time points for the Study Product
group. No such difference is observed (P = .338) in the
variance of the Placebo group between day 5 (0.0532 –
0.0019 mi) and day 0 (0.0541 – 0.0021 mi), or between day 5
and any of the other time points. As the distributions merge
toward the higher performing end of the distributions, and
the widest variance is seen at the lower initial performing
end of the distribution, these data suggest a narrowing of the
population distribution toward the lowest performing end
of the distribution in the Study Product group. This result
coupled with the average individual performance improve-
ment seen by day 84 (Table 3) strongly suggests that the
Study Product provides the most immediate benefit to the
most initially compromised individuals but will eventually
benefit walking functions in all individuals experiencing OA
in the knee.
These results are corroborated by CIOBP analysis in
which individual benefits from the study product are cor-
related to baseline performance (Fig. 6). After 5 days of
Study Product use, the individual performance difference
over baseline for the Study Product users (slope of the
correlation, -0.533 – 0.078) was statistically greater than
zero (P < .00001) and greater than that of the Placebo group
(-304 – 0.106, P = .004). The Placebo group also showed
statistical improvement over the first 5 days but not to as
large an extent as the Study Product group, which might
reflect the benefits of increased exercise over their normal
activity. These data suggest that those with demonstrably
Table 1. Population Distributions in Western Ontario
McMaster Osteoarthritis Index Stiffness Subscale Scores
for the Study Product and Placebo Cohorts
Score 0–8
No. in Study Product Cohort
Baseline Day 5 Day 28 Day 56 Day 84
0–1 3 5 7 12 13
2 4 10 12 9 10
3 10 11 4 3 4
4 12 8 10 9 5
5 8 4 3 3 6
6 3 3 5 5 1
7–8 3 2 2 0 2
v2 P-score .3887 .0181 .2118 .3137 .1676
Score 0–8
No. in Placebo Cohort
Baseline Day 5 Day 28 Day 56 Day 84
0–1 5 8 8 11 11
2 3 6 12 9 15
3 12 5 8 9 4
4 12 11 11 9 8
5 8 8 4 2 3
6 5 6 2 3 2
7–8 0 1 0 0 0
Chi-squared statistical analysis suggests a statistical improvement in the
Study Product cohort over Placebo at day 5.
Table 2. Population Distributions
in the Change-Over-Baseline Scores for the Western
Ontario McMaster Osteoarthritis Index
Stiffness Subscale
Score (-6 to 3)
No. in Study Product Cohort
Baseline Day 5 Day 28 Day 56 Day 84
-6 to -3 1 7 10 9
-2 7 12 9 10
-1 16 4 6 10
0 14 10 8 3
1 4 3 5 8
2–3 1 5 3 1
v2 P-score 0.0365 0.1263 0.6975 0.0068
Score (0–8)
No. in Placebo Cohort
Baseline Day 5 Day 28 Day 56 Day 84
-6 to -3 1 6 9 11
-2 3 7 7 8
-1 13 11 8 8
0 14 15 12 11
1 10 4 5 3
2–3 4 2 2 2
Chi-squared analysis confirms that the Study Product cohort showed
significant improvement over Placebo at both day 5 (confirming the results of
Table 1) and day 84.
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compromised load-bearing performance can expect to ex-
perience significant improvement with Study Product use
within 5 days, and that performance improvement will
persist over time with continued use. However, those
without demonstrable performance impairment will see lit-
tle immediate benefit from using Study Product but do still
appear to improve with Study Product versus Placebo over
longer time (Table 1). The data demonstrate that there was
a 75% relative improvement for the Study Product group
over the Placebo group [(-0.53274) - (0.30365)/(0.030364) ·
100 = 75.45%].
Range of ROM testing (goniometer). Knee extension
and knee flexion were measured by a goniometer. When
compared with baseline, a statistically significant increase
was observed at Visit 4 for knee flexion in the Study Product
group. The mean change from baseline (SD) in the Study
Product group at Visit 4 was -0.2 (4.75) (P < .05); the mean
change from baseline (SD) in the Placebo group at Visit 4
was -0.3 (3.65) (P > .05). When compared for study dura-
tion between groups, no statistically significant difference
was reported in knee extension and flexion.
Safety results
During the study period, 17 AEs were reported in 9
subjects (20.5%) of the Study Product group and 6 AEs
FIG. 5. The population distributions of 6MWT results for the (a)
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were reported in 6 subjects (13.6%) of the Placebo group.
This comparative difference was not statistically significant
(P > .05). There was one SAE reported in one subject (2.3%)
of the Study Product group in this study. All AEs were
analyzed by groups. Of the 17 AEs reported in 9 subjects of
the Study Product group, the severity of all AEs was mild
and these included nasopharyngitis (6.8%), diarrhea (2.3%),
nausea (2.3%), vomiting (2.3%), chest pain (2.3%), influenza-
like illness (2.3%), abnormal hepatic function (2.3%), irreg-
ular heart rate (2.3%), dehydration (2.3%), dizziness (2.3%),
headache (2.3%), poor-quality sleep (2.3%), cough (2.3%),
rhinorrhea (2.3%), and rash (2.3%). Regarding the causality
or relationship of AEs to Study Product, two Study Products
potentially related to AEs such as headache and poor-quality
sleep were reported in two subjects. One SAE such as de-
hydration was reported in one subject and this subject with-
drew from the study. The SAE revealed itself as the study
subject was hospitalized for acute and chronic alcohol tox-
icity, which was considered unrelated to the study product.
Of the six AEs reported in six subjects of the Placebo group,
these were abdominal pain (2.3%), flatulence (2.3%), nausea
(2.3%), labyrinthitis (2.3%), hypoaesthesia (2.3%), and si-
nus operation (2.3%). Regarding the severity of AE inci-
dence, the severity for abdominal pain and hypoaesthesia
was moderate, plus the notation of four AEs measured was
mild (flatulence, nausea, labyrinthitis, and sinus operation).
Two placebo-related AEs such as abdominal pain and nau-
sea were reported in two subjects, and the dose of placebo
was discontinued due to one placebo-related AE (nausea).
No SAE was reported in the Placebo group. Overall, no sub-
ject in either group had clinically significant abnormality or
concerns in physical examination, vital signs, hematology,
and chemistry assessment during the study period. The study
did not find cause for safety concern of either the Study
Product or Placebo.
DISCUSSION
Discomfort may impact joint mobility and impact our
ability to exercise, carry out typical tasks of daily living,
especially if occurring at the level of the hips, knees, lower
back, and so forth. Impaired joint mobility may also impact
quality of life. It is for these reasons that the results of this
study hold interest. This study was able to determine that for
those who have a harder time ambulating because of their
joint discomfort/OA, the WSEM Study Product could sig-
nificantly enhance physical capacity (ability to walk and
cover distance) as well as feelings of stiffness (joint stiff-
ness) to a greater and more meaningful degree than the
placebo product. Medicinal studies with OA have previ-
ously found that it is those with the most severe forms of the
condition that achieve the greatest clinically relevant im-
provement.31 Our results are consistent with this previous
finding. This early relief or improvement may help spur a
person to continued practices for maintaining improved
joint health. In this study, which included adults with OA, it
was decided to examine whether the OA interacts with and
impacts the ability to ambulate (physical activity) as well as
quality of life. Based on their initial results, subjects were
classified by their ability to do load-bearing work (ambulate
efficiently); it was found that subjects with initial apparent,
compromised load-bearing performance had significant
improvement with the administration of the study product
within 5 days (the 6MWT and WOMAC-stiffness score,
both significantly improved), and that the performance im-
provement was maintained in the 6MWT over the course of
the study.
Those who were worse off physically (poorer perform-
ers on the 6MWT) experienced a meaningful improve-
ment in their physical abilities and quality of life (perceived
stiffness) compared with those who were less physically
FIG. 6. Observed change in miles walked by indi-
viduals over the initial 5-day period as a function of
their initial (day 0) performance. The correlation of
improvement with initial performance for the Study
Product is statistically valid at >99.9% confidence
(P-score <.0001), and for Placebo, at 99.3% confidence
(P-score = .0065). The increase in the correlation slope
was greater for the Study Product group than the control
(Placebo) group at >98% confidence (P-score = .01981).
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compromised (as detailed by 6MWT and WOMAC-stiffness
scores on day 5, P < .05). Overall, when compared with
baseline, statistically significant decreases were observed
until the end of the study in subscales and total score of
WOMAC in both study groups and there was no statistically
significant difference between groups (P > .05). The study
product group had some improvement in knee function
when compared with baseline and showed significant im-
provement in physical performance, mobility, and joint
stiffness in 5 days when compared with the placebo (P < .05)
across outcomes listed. These improvements appeared to be
maintained over the *12 weeks of the study. The con-
sumption of Study Product and Placebo over the 12 weeks of
the study (looking at end of study data vs. baseline) was
found not to differently effect WOMAC pain, WOMAC
physical function, the 6MWT, or ROM.
The fact that the findings of this study are supported by
prior published research using this direct tested Study Pro-
duct (BiovaFlex) or one in the same food category (egg shell
membrane) should bolster the strength of the findings due to
consistency of the results.16–18,30,31 In addition, with the
understanding that GAGs are a component of the WSEM
(e.g., chondroitin and hyaluronan), there are also prior pub-
lished data demonstrating the benefits of GAGs for quality
of life and joint function and ability in those with joint
health issues or OA; hence, the findings of this study appear
well supported.9–11,30,31
From a safety perspective, this 12-week study results
supported safety as measured by blood tests (metabolic
panel, complete blood count with differential), vitals (sys-
tolic and diastolic blood pressure, heart rate), subjective
statements by the participant or direct observation or as-
sessment by the study physician for both Study Product and
the Placebo. There were no signals of any human safety
concerns.
Limitations of this study may include an OA population
that was not defined by grade (ACR criteria), not specifically
recruiting people with radiographic moderate to severe OA.
There is an unequal distribution of women to men, which
might be considered a weakness but is known of the prev-
alence of knee OA in that it is more prevalent in women.
A further weakness is that we did not collect any biomarkers
related to inflammation or bone or cartilage health. Future
studies may consider adding more outcome-based objective
markers for detailing efficacy.
In conclusion, this study found that for those who are
physically compromised in their ability to ambulate (walk
slower due to their joint discomfort or pain), 450 mg of the
Study Product (BiovaFlex) had a positive impact on func-
tional capacity (ability to ambulate) as well as on per-
ceived joint stiffness within the initial 5 days of dosing.
This improvement was also considered meaningful as it was
maintained over the course of the study (12 weeks).
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